Macrocyclic compound and use thereof
By designing compounds with specific structures as RAS inhibitors, the problem of ineffective treatment of cancers with KRASG12V and KRASG12D mutations in existing technologies has been solved, achieving effective inhibition of the RAS signaling pathway and broad-spectrum cancer treatment.
WO2026153217A1PCT designated stage Publication Date: 2026-07-23LINGANG LAB +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- LINGANG LAB
- Filing Date
- 2026-01-08
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Current technologies lack effective broad-spectrum RAS inhibitors, especially for cancers with KRASG12V and KRASG12D mutations.
Method used
A compound of general formula (I) or general formula (X) and its stereoisomers, transisomers, geometric isomers, tautomers or pharmaceutically acceptable salts thereof, constituted by a specific group composition and linkage, is provided as a RAS inhibitor for the treatment of cancers caused by RAS mutations.
Benefits of technology
This compound can effectively inhibit the RAS signaling pathway and has the potential for wide application in the treatment of cancers carrying mutations such as KRASG12V and KRASG12D, providing a treatment option for RAS-mutant cancers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2026071411_23072026_PF_FP_ABST
Abstract
Provided are a macrocyclic compound and the use thereof. The compound has a structure as represented by formula (I-1), where the definition of each substituent is as described in the description and the claims. The compound is used as an RAS inhibitor for preventing and / or treating RAS-mutant tumors.
Need to check novelty before this filing date? Find Prior Art